PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent H.C. Wainwright & Co. research report. The report “is initiating coverage on PaxMedica, an emerging firm developing novel formulations of suramin for treatment of neurological disorders with intractable symptoms,” which is “attacking autism with a novel approach.” … Continue reading InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Recent H.C. Wainwright & Co. Research Report with ‘Buy’ Rating, $3 PT